TACSTD2 and breast cancer: Preclinical studies have identified several promising BC antigens for CAR T cell therapy, including EGFR, FRα, HER2, integrin αvβ3, AXL, NKG2D, c‐Met, MUC1, mesothelin, ROR1, TROP2, and TEM8.